Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe
as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also
determine if using Abraxane will allow patients to receive treatment every two weeks without
requiring injects of G-CSF, a white blood cell stimulating growth factor.
Phase:
N/A
Details
Lead Sponsor:
Harold J. Burstein, MD, PhD
Collaborators:
Beth Israel Deaconess Medical Center Celgene Corporation Massachusetts General Hospital